IBC Life Sciences, Sheraton Miyako Tokyo Japan
2-4 March 2011
Get a comprehensive scientific update on: - Delivery technologies including intracellular targeting, chemical modifications, oral, liposomal and nanoparticle delivery
- Understanding of microRNA from Santaris, miRagen and University of Tokyo
- Manufacturing and analytical development for peptides and oligos
- Regulatory considerations and guidance updates from Oligo Safety Working Group, ICHS6 and Regado
- Valuable data on preclinical data and therapeutic candidates from around the world
- Challenges and solutions for the delivery of siRNA and Peptide Therapeutics
AsiaTIDES 2011 also provides the rare and perfect opportunity to develop new business collaborations and potential partnerships with international companies without leaving Japan. With so many US and European pharmaceutical companies forming alliances with Japanese companies, there is an important opportunity not to be missed here. Conference Sessions Include: - Keynote Presentations addressing Drug Delivery Challenges and Solutions
- Update on Oligonucleotide-Based Therapeutics in Preclinical and Clinical Development
- Updates on Peptide-Based Therapeutics in Preclinical and Clinical Development
- Manufacturing and Analytical Development for Peptides and Oligos
- Formulation and Delivery of Peptides and Oligos
- Business Considerations and Market Overviews
- Regulatory Updates
Conference Tutorials Include: - Bioanalytical Techniques for Oligonucleotides and Peptides
Lessons Learned on the Way to an IND from Real Life Experience with Oligonucleotides and Peptides
|
|
|
Invited Speakers:
|
|
Pieter R. Cullis, Ph.D.
Professor, Biochemistry and Molecular Biology
University of British Columbia, Canada Kazunori Kataoka, Ph.D.
Professor, Materials Engineering and Center for Disease Biology and Integrated Medicine
University of Tokyo, Japan Kazunori Kataoka, Ph.D.
Professor, Materials Engineering and Center for Disease Biology and Integrated Medicine
University of Tokyo, Japan
Eric Tomlinson, Ph.D., D.Sc.
President and Chief Executive Officer
Altea Therapeutics Corporation, USA Daphna Heffetz, Ph.D.
Chief Executive Officer and Director
TransPharma Medical Ltd, Israel Tomi K. Sawyer, Ph.D.
Senior Vice President and Chief Scientific Officer
Aileron Therapeutics Inc., USA
|
|